Unlock instant, AI-driven research and patent intelligence for your innovation.

Application of a monoclonal antibody in the treatment of neurodegenerative diseases

A monoclonal antibody and neurodegenerative technology, applied in the direction of nervous system diseases, antibodies, nervous system cells, etc., can solve the problems of inability to alleviate pathological damage of neuroinflammation and complicated pathogenesis

Active Publication Date: 2018-06-19
INNOVENT BIOLOGICS (SUZHOU) CO LTD
View PDF4 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The etiology of AD is very complex and has not yet been clarified exactly.
[0003] At present, the main clinical drug for the treatment of AD is donepezil, which is a cholinesterase inhibitor. It can improve learning and memory by reducing the degradation of acetylcholine. It can only relieve the symptoms of learning and memory impairment in AD patients, but cannot reduce neuroinflammation. , senile plaque deposition and other pathological damage

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of a monoclonal antibody in the treatment of neurodegenerative diseases
  • Application of a monoclonal antibody in the treatment of neurodegenerative diseases
  • Application of a monoclonal antibody in the treatment of neurodegenerative diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0125] Example 1 Affinity determination of recombinant human anti-tumor necrosis factor-α monoclonal antibody and soluble TNF-α

[0126] 1. Experimental materials

[0127] Experimental drug: recombinant human anti-tumor necrosis factor-α monoclonal antibody injection, the sequence of which is shown in SEQ ID NO.: 1, stored in a refrigerator at 4°C.

[0128] Recombinant human TNF-α: purchased from Shanghai Nearshore Protein Technology Co., Ltd., item number: C008, batch number: 0327018.

[0129] Amine Coupling Kit (Lot No. 2057704), HBS-EP+buffer (10×) (Lot No. BCBJ0266V), Human Antibody Capture Kit (Lot No. 10137214): all purchased from GE Healthcare.

[0130] Biacore T200, CM5 sensor chip (Serial No. 10148134): purchased from GE Healthcare.

[0131] 2. Experimental method

[0132] 2.1 Solution preparation

[0133] Mobile phase buffer solution: HBS-EP + Buffer solution (10 mM HEPES, 150 mM NaCl, 3 mM EDTA, 0.05% P20, pH 7.4).

[0134] Sample dilution solution: HBS-EP + ...

Embodiment 2

[0145] Example 2 Recombinant human anti-tumor necrosis factor-alpha monoclonal antibody binding specificity

[0146] 1. Experimental materials

[0147] Test product: recombinant human anti-tumor necrosis factor-α monoclonal antibody injection, the sequence of which is shown in SEQ ID NO.: 1, stored in a refrigerator at 4°C.

[0148] Recombinant human TNF-β: purchased from Sino Biological Inc., product number: 10270-HNAE, lot number: LC05JL0410; recombinant monkey TNF-α: purchased from Sino Biological Inc., product number: 90018-CNAE, lot number: LC06DE1213; recombinant dog TNF-α: purchased from Sino Biological Inc., product number: 70003-DNAE, lot number: LC05JU2002; recombinant mouse TNF-α: purchased from Shanghai PrimeGene Bio-Tech Co., Ltd. company, product number: 123-01, lot number : 810588; recombinant rat TNF-α: purchased from Shanghai PrimeGene Bio-Tech Co., Ltd. company, item number: 143-01, batch number: Y14301011; goat anti-human IgG-HRP absorbed by monkey serum wi...

Embodiment 3

[0156] Example 3 Inhibitory Effect of Recombinant Human Anti-TNF-α Monoclonal Antibody on the Binding of TNF-α to Its Receptor

[0157] 1. Experimental materials

[0158] Test product: recombinant human anti-tumor necrosis factor-α monoclonal antibody injection, the sequence of which is shown in SEQ ID NO.: 1, stored in a refrigerator at 4°C.

[0159] Recombinant human TNF-α was purchased from Shanghai Jinan Protein Technology Co., Ltd., product number: C008, batch number: 0327018; recombinant TNF RI (p55) and TNF RII (p75) were purchased from R&D Company, product number 372-R1-050 and 726, respectively -R2-050, the batch numbers are APJ0712071 and BVD0312111 respectively; goat anti-human IgG-Fc was purchased from Kirkegaard & Perry Laboratories, Inc., product number: 01-10-20, batch number: 110078; BSA was purchased from Roche Company, batch number: 10735078001.

[0160] 2. Experimental steps

[0161] (1) Dilute 1 mg / ml goat anti-human IgG-Fc to 10 μg / ml with PBS, add 50 μl...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
concentrationaaaaaaaaaa
concentrationaaaaaaaaaa
concentrationaaaaaaaaaa
Login to View More

Abstract

The invention discloses an application of a monoclonal antibody in treatment of neurodegenerative diseases, and particularly provides a uses of a monoclonal antibody. The monoclonal antibody is used for preparing a medicine composition treating the neurodegenerative diseases. The sequence of the monoclonal antibody is shown as SEQ ID NO.1. Experiments show that the monoclonal antibody and a preparation thereof have a significant treating function for the neurodegenerative diseases, and the function is obviously dose-dependent.

Description

technical field [0001] The term biomedical field of the present invention, specifically, relates to the application of a monoclonal antibody in neurodegenerative diseases. Background technique [0002] Alzheimer's disease (AD) is a chronic and progressive neurodegenerative disease, the main clinical manifestations are the continuous decline of cognitive function, accompanied by a variety of behavioral abnormalities, and eventually lead to death. AD mainly includes familial and sporadic: the former has early onset and is related to amyloid precursor protein (amyloid precursor protein, APP), presenilin 1 (presenilin 1, PS 1) and presenilin 2 (presenilin 2, PS2) gene mutations ; There are many cases of the latter, most of which come on after the age of 65, and are related to the polymorphism of apolipoprotein E (Apolipoprotein E, ApoE). AD currently ranks sixth among all causes of death and fifth among those over 65 years of age. In 2010, there were 36 million AD cases worldw...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K39/395A61K47/18A61P25/28A61P29/00A61P25/16A61P9/10C12N5/079
Inventor 王春明李佳俞德超
Owner INNOVENT BIOLOGICS (SUZHOU) CO LTD